Melissa L Johnson

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
    Melissa L Johnson
    Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer 119:356-62. 2013
  2. ncbi Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Melissa L Johnson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Thorac Oncol 6:1128-31. 2011
  3. ncbi Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5840-7. 2012
  4. ncbi A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
  5. ncbi Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    J Clin Oncol 29:2066-70. 2011
  6. ncbi Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
    Marie Brevet
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Lung Cancer 73:96-102. 2011
  7. ncbi Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6169-77. 2012
  8. ncbi Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
    J Matthew Reinersman
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:28-31. 2011
  9. ncbi Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
    Anna M Varghese
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 8:123-5. 2013

Collaborators

Detail Information

Publications9

  1. ncbi Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
    Melissa L Johnson
    Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer 119:356-62. 2013
    ..For the current report, the authors examined the association of EGFR and KRAS mutations with survival among patients with advanced lung adenocarcinomas...
  2. ncbi Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Melissa L Johnson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Thorac Oncol 6:1128-31. 2011
    ..The SRC inhibitor dasatinib demonstrates antitumor activity in gefitinib-resistant cells lines and xenografts. Dasatinib is tolerable for patients with advanced non-small cell lung cancer, and in combination with erlotinib...
  3. ncbi Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:5840-7. 2012
    ..In this study, the authors hypothesized that smoking-dependent differences in the distribution of driver mutations may explain differences in prognosis between these subgroups...
  4. ncbi A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
    ..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations...
  5. ncbi Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    J Clin Oncol 29:2066-70. 2011
    ..EGFR mutations underlie the sensitivity of lung cancers to erlotinib and gefitinib and can occur in any patient with this illness. Here we examine the frequency of EGFR mutations in smokers and men...
  6. ncbi Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
    Marie Brevet
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Lung Cancer 73:96-102. 2011
    ..In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer...
  7. ncbi Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6169-77. 2012
    ..The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear...
  8. ncbi Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
    J Matthew Reinersman
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:28-31. 2011
    ..KRAS mutations confer resistance to EGFR-tyrosine kinase inhibitors. The prevalence of these mutations in African American patients has not been thoroughly investigated...
  9. ncbi Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
    Anna M Varghese
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 8:123-5. 2013
    ....